Basic Information
IBRANCE CAPSULE 75mg
CAPSULE
Regulatory Information
SIN15048P
July 21, 2016
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
Company Information
Active Ingredients
Palbociclib
Strength: 75.000mg
Detailed Information
Contraindications
**4.3. Contraindications** None
Indication Information
**4.1. Therapeutic indications** Ibrance is indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: - an aromatase inhibitor as initial endocrine-based therapy; or - fulvestrant in patients with disease progression following endocrine therapy.